DeJarnette Research Systems has decided to withdraw from the IBM consortium participating in the U.S. military's Digital Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) deal. The Towson, MD-based firm had been contributing its
DeJarnette Research Systems has decided to withdraw from the IBM consortium participating in the U.S. military's Digital Imaging Network-Picture Archiving and Communications Systems (DIN-PACS) deal. The Towson, MD-based firm had been contributing its connectivity products to IBM as part of the team, but will no longer be involved in the engineering and product improvement plans on the project.
DeJarnette elected to withdraw from formal participation on the IBM team due to differences in corporate goals, technical direction, and business objectives between the two companies, said president Wayne DeJarnette. He declined to provide further details on the differences, other than to say that cultural differences between the companies led him to make the decision.
The company said that its decision will not affect its relationships with Department of Defense customers, however. The company anticipates it will contribute its products on an OEM basis to IBM and will continue to sell its products into other military accounts.
Although some analysts had estimated DIN-PACS spending to reach $165 million this year (PNN 6/98), actual awards to date have been under $35 million. This was not a factor in the decision to withdraw, however, DeJarnette said.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.